🟢 Pacific Biosciences is trading 8.8% up as biotech strength may support momentum

Pacific Biosciences is trading at $2.67, up 8.78%, with biotech-sector strength potentially contributing to the advance.

• No new company-specific announcement explaining the October 28 move was identified; the latest listed PacBio release is its October 19 Verily collaboration.
• The supplied sector context shows XBI up 2.18% amid positive clinical-trial and regulatory news.
• The advance extends consecutive gains, including an 8.89% rise on October 27; available evidence points to sector support and momentum, not a confirmed company-specific catalyst.